Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc.

Penta Teknoloji Urunleri Dagitim Ticaret AS ( ($TR:PENTA) ) has provided an update. Trading in Penta Teknoloji’s PENTA.E shares on Borsa Istanbul w...

Borsa Istanbul Triggers Circuit Breaker on Penta Teknoloji Shares

The latest announcement is out from Denta Water and Infra Solutions Limited ( ($IN:DENTA) ). Denta Water and Infra Solutions Limited has scheduled ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$12.52	-1.42%	277.68K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$12.52	-1.4%	277.68K
3
4
5
6

ENTA

Get Enanta Pharmaceuticals, Inc. Data in Excel

Get Enanta Pharmaceuticals, Inc. Data in Excel